QURE Stock Overview
Develops treatments for patients suffering from rare and other devastating diseases. More details
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 2/6 |
| Dividends | 0/6 |
uniQure N.V. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$5.78 |
| 52 Week High | US$11.35 |
| 52 Week Low | US$3.73 |
| Beta | 0.90 |
| 11 Month Change | -11.55% |
| 3 Month Change | -4.93% |
| 1 Year Change | -17.66% |
| 33 Year Change | -79.73% |
| 5 Year Change | -89.45% |
| Change since IPO | -60.44% |
Recent News & Updates
uniQure's Yellow Flags: Early-Stage Gene Therapies Amid Restructuring
Oct 21uniQure: Pullback After Strong Interim Treatment Data Creates Buying Opportunity
Aug 06Recent updates
uniQure's Yellow Flags: Early-Stage Gene Therapies Amid Restructuring
Oct 21uniQure: Pullback After Strong Interim Treatment Data Creates Buying Opportunity
Aug 06uniQure N.V. (NASDAQ:QURE) Analysts Are Cutting Their Estimates: Here's What You Need To Know
Aug 03
uniQure: Positive HD AMT-130 Treatment Data Leads To Several Other Catalysts
Jul 09Earnings Update: uniQure N.V. (NASDAQ:QURE) Just Reported And Analysts Are Trimming Their Forecasts
Mar 03uniQure: The Valuation Got More Attractive
Feb 01Little Excitement Around uniQure N.V.'s (NASDAQ:QURE) Revenues As Shares Take 29% Pounding
Jan 17A Look At The Fair Value Of uniQure N.V. (NASDAQ:QURE)
Dec 15Revenue Downgrade: Here's What Analysts Forecast For uniQure N.V. (NASDAQ:QURE)
Aug 27Analysts Are More Bearish On uniQure N.V. (NASDAQ:QURE) Than They Used To Be
Aug 06Here's Why uniQure (NASDAQ:QURE) Can Manage Its Debt Despite Losing Money
Aug 02uniQure N.V. (NASDAQ:QURE) Looks Inexpensive After Falling 43% But Perhaps Not Attractive Enough
Jul 02Analyst Forecasts For uniQure N.V. (NASDAQ:QURE) Are Surging Higher
Jun 28uniQure N.V. (NASDAQ:QURE) Analysts Are Reducing Their Forecasts For This Year
May 14Is uniQure (NASDAQ:QURE) Using Debt Sensibly?
Apr 11News Flash: 15 Analysts Think uniQure N.V. (NASDAQ:QURE) Earnings Are Under Threat
Mar 01Does uniQure (NASDAQ:QURE) Have A Healthy Balance Sheet?
Dec 09uniQure: Clinical Risk, A Critical Upcoming Catalyst And A Cash Cushion
Sep 21uniQure N.V.: 2 Possible Regulatory Approvals Makes This A Must Watch
Aug 30uniQure N.V. (NASDAQ:QURE) Analysts Are Reducing Their Forecasts For This Year
Aug 14uniQure plunges 27% on Q2 revenue miss, postpones higher dose trial of Huntington’s disease therapy
Aug 08These 4 Measures Indicate That uniQure (NASDAQ:QURE) Is Using Debt Safely
Jun 08uniQure N.V. (NASDAQ:QURE) Analysts Are Reducing Their Forecasts For This Year
May 04uniQure N.V.: Worth A Look Based On Hemophilia B Marketing Applications
Apr 08We Think That There Are Issues Underlying uniQure's (NASDAQ:QURE) Earnings
Mar 04The Consensus EPS Estimates For uniQure N.V. (NASDAQ:QURE) Just Fell Dramatically
Feb 27Is uniQure (NASDAQ:QURE) A Risky Investment?
Feb 23uniQure: Betting On Hemophilia-B Cure
Jan 18Shareholder Returns
| QURE | US Biotechs | US Market | |
|---|---|---|---|
| 7D | -6.5% | 2.5% | 2.2% |
| 1Y | -17.7% | 16.1% | 31.6% |
Return vs Industry: QURE underperformed the US Biotechs industry which returned 16.1% over the past year.
Return vs Market: QURE underperformed the US Market which returned 31.6% over the past year.
Price Volatility
| QURE volatility | |
|---|---|
| QURE Average Weekly Movement | 13.2% |
| Biotechs Industry Average Movement | 9.8% |
| Market Average Movement | 6.3% |
| 10% most volatile stocks in US Market | 15.7% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: QURE's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: QURE's weekly volatility (13%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1998 | 480 | Matt Kapusta | www.uniqure.com |
uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases. It offers HEMGENIX that has completed Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also develops AMT-130, a gene therapy that is in Phase I/II clinical study for the treatment of Huntington’s disease. In addition, it is developing AMT-162, which is in preclinical trial for the treatment of superoxide dismutase 1- amyotrophic lateral sclerosis; AMT-260 that is in preclinical trial to treat temporal lobe epilepsy; AMT-191, which is in preclinical trial for the treatment of fabry disease; AMT-161 that is in preclinical trial to treat amyotrophic lateral sclerosis caused by mutations; AMT-240, which is in preclinical trial to for the treatment of autosomal dominant Alzheimer’s disease; and AMT-210 that is in preclinical trial to treat Parkinson’s disease.
uniQure N.V. Fundamentals Summary
| QURE fundamental statistics | |
|---|---|
| Market cap | US$281.74m |
| Earnings (TTM) | -US$239.50m |
| Revenue (TTM) | US$28.59m |
9.9x
P/S Ratio-1.2x
P/E RatioIs QURE overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| QURE income statement (TTM) | |
|---|---|
| Revenue | US$28.59m |
| Cost of Revenue | US$182.66m |
| Gross Profit | -US$154.08m |
| Other Expenses | US$85.43m |
| Earnings | -US$239.50m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -4.91 |
| Gross Margin | -538.97% |
| Net Profit Margin | -837.80% |
| Debt/Equity Ratio | 856.0% |
How did QURE perform over the long term?
See historical performance and comparison